By Fineline Cube 
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the completion of the first patient dosing for its self-developed ABSK131. This highly selective small-molecule PRMT5×MTA inhibitor marks a significant milestone in the company’s oncology pipeline.
ABSK131’s Mechanism and Advantages
ABSK131 is designed to target PRMT5 and MTA with strong anti-tumor activity. Preclinical studies demonstrated excellent selectivity for MTAP-deficient tumor cells, along with favorable pharmacokinetic and pharmacodynamic properties. These characteristics position ABSK131 as a promising therapeutic candidate in oncology.
Clinical Progress
The successful first-patient dosing represents a key step forward in Abbisko’s clinical development strategy. The company is committed to advancing ABSK131 through clinical trials to evaluate its safety and efficacy in treating cancers with unmet medical needs.-Fineline Info & Tech